HOOKVAC

Developing and Testing a novel, low-cost, effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries

Coordinatore	Academisch Medisch Centrum bij de Universiteit van Amsterdam    more  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Mr. Nome: Friso Cognome: Janssen Email: send email Telefono: +31 20 5667800
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	7˙669˙416 €
EC contributo	5˙999˙983 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2017-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Academisch Medisch Centrum bij de Universiteit van Amsterdam  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Mr. Nome: Friso Cognome: Janssen Email: send email Telefono: +31 20 5667800	NL (AMSTERDAM)	coordinator	1˙773˙844.00
2	Q-BIOLOGICALS NV  Organization address address: TECHNOLOGIEPARK 4 city: GENT postcode: 9052 contact info Titolo: Prof. Nome: Annie Cognome: Van Broekhoven Email: send email Telefono: +32 92411103	BE (GENT)	participant	1˙589˙690.00
3	Nome Ente NON disponibile	GA	participant	994˙800.00
4	ALBERT B. SABIN VACCINE INSTITUTE INC  Organization address address: PENNSYLVANIA AV NW SUITE 7100 2000 city: WASHINGTON DC postcode: 20006 contact info Titolo: Mr. Nome: Brian Cognome: Davis Email: send email Telefono: +1 2028428610	US (WASHINGTON DC)	participant	420˙816.00
5	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Maria Cognome: Yazdanbakhsh Email: send email Telefono: +31 715265067	NL (LEIDEN)	participant	400˙230.00
6	Pharmidex Pharmaceutical Services Limited  Organization address address: HANOVER STREET 14 FLOOR 3 city: LONDON postcode: W1S 1RR contact info Titolo: Dr. Nome: Mo Cognome: Alavijeh Email: send email Telefono: +44 870 240 5978 Fax: +44 845 125 8956	UK (LONDON)	participant	352˙291.00
7	GEORGE WASHINGTON UNIVERSITY CORPORATION  Organization address address: EYE STREET NW 2121 city: WASHINGTON DC postcode: 20052 contact info Titolo: Ms. Nome: Jackie Cognome: Bendall Email: send email Telefono: +1 202 994 6255	US (WASHINGTON DC)	participant	221˙747.00
8	BAYLOR COLLEGE OF MEDICINE CORPORATION - BCM  Organization address address: ONE BAYLOR PLAZA T119 city: HOUSTON postcode: 77030 contact info Titolo: Dr. Nome: Leanne B. Cognome: Scott Email: send email Telefono: +1 713 7986978	US (HOUSTON)	participant	198˙631.00
9	EBERHARD KARLS UNIVERSITAET TUEBINGEN  Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Mrs. Nome: Ilka Cognome: Westermann Email: send email Telefono: +49 70712982191	DE (TUEBINGEN)	participant	47˙934.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years. HOOKVAC will be developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. This will be done in Gabon in a very typical setting within the Central African rainforest belt, where the incidence of hookworm infections is 30%. Inspired by preparatory research, HOOKVAC believes that it can develop the vaccine with at least 80% efficacy against moderate and heavy hookworm infections that lasts at five years after immunization. Cost effectiveness modelling has shown that such a vaccine will significantly improve the efficacy of the current mass drug administration programs. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas. Via a program of 48 months with 6 work packages, HOOKVAC will address 4 main objectives: (1) establish safety and immunogenicity of the vaccine candidate in an endemic population (2) improve the manufacturing process (3) provide clinical proof of concept (4) improve accessibility of the vaccine in endemic areas. The involvement of European SMEs in the project is a critical component to advancing a successful vaccine, and an integral part of adding private sector know-how and scientific expertise to the project. This will inspire other European SMEs to become more involved in public/private vaccine product development for neglected infectious diseases. By doing so, HOOKVAC will fuel a follow-up programme for further development of the vaccine towards into a licensed product.